Barclays Issues Pessimistic Forecast for LivaNova (NASDAQ:LIVN) Stock Price

LivaNova (NASDAQ:LIVN) had its target price decreased by analysts at Barclays from $58.00 to $56.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Barclays‘s target price would indicate a potential upside of 40.04% from the stock’s current price.

A number of other analysts also recently weighed in on LIVN. Mizuho cut their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Needham & Company LLC cut their target price on LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. StockNews.com downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 26th. Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Finally, Stifel Nicolaus reduced their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, LivaNova has a consensus rating of “Moderate Buy” and a consensus price target of $61.17.

LivaNova Trading Down 2.2 %

Shares of NASDAQ:LIVN opened at $39.99 on Friday. The company has a market capitalization of $2.17 billion, a P/E ratio of 95.21 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The business’s 50 day simple moving average is $46.93 and its 200 day simple moving average is $49.37. LivaNova has a 1 year low of $39.42 and a 1 year high of $64.47.

Insider Transactions at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.27% of the stock is owned by company insiders.

Institutional Trading of LivaNova

Several institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its holdings in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after purchasing an additional 219 shares during the last quarter. Sterling Capital Management LLC increased its position in shares of LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after buying an additional 1,441 shares during the period. Central Pacific Bank Trust Division raised its stake in LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after buying an additional 720 shares during the last quarter. Vestcor Inc acquired a new position in LivaNova in the fourth quarter valued at $204,000. Finally, Optimize Financial Inc acquired a new position in LivaNova in the fourth quarter valued at $208,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.